This clinical trial is focused on studying the effects of certain medications on patients with solid tumors, which are abnormal masses of tissue that usually do not contain cysts or liquid areas. The study involves the use of medications known as immune checkpoint inhibitors (ICIs), which are treatments that help the immune system recognize and attack cancer cells. Some of the ICIs being studied include atezolizumab, durvalumab, nivolumab, ipilimumab, pembrolizumab, avelumab, and cemiplimab. These medications are often used alone or in combination with other treatments like chemotherapy or targeted therapy.
The purpose of this study is to explore the value of immune markers present in the blood to identify biomarkers for immune-related toxicities of these checkpoint inhibitors. This means researchers are looking for specific signs in the blood that might predict how a patient will react to the treatment. The study will monitor changes in these immune markers at different times during the treatment and when any immune-related side effects occur. The study will also assess the safety of these treatments by recording any adverse events, which are any unwanted effects experienced by participants during the study.
Participants in the study will receive the treatments over a period of up to 12 months. The medications are administered through an intravenous infusion, which means they are given directly into a vein. The study aims to gather information that could help improve the understanding of how these treatments work and how they might cause side effects, ultimately leading to better care for patients with solid tumors.
Belgium 
